Abstract:Background: The somatic mutations that drive acute myeloid leukaemia (AML) are highly heterogenous. Identifying the mutations that drive individual cases can help determine patient prognosis and therapy. For this reason, genetic testing for prognostically important mutations in leukaemic DNA is now routine in many diagnostic laboratories. Also, the analysis of gene-expression profiles from AML RNA can provide additional clinically useful information that cannot be inferred from DNA sequencing. Whilst it is both expensive and impractical to carry out both types of sequencing and analyses, we hypothesised that the two could be combined more cheaply and effectively if the presence of mutations in prognostically important gene mutations could be identified from RNA-seq data. However, computational methodologies for robust detection of the diverse types of somatic mutations found in AML such as substitutions, indels, tandem duplications and translocations, are not currently available. Aims: To develop an stand-alone, lightweight and use-friendly software for the identification of clinically relevant mutations from AML RNA-seq data. Methods: To ensure efficient mapping of RNA-seq reads, we hash-indexed the DNA sequences of target genes using 10-mer sliding windows and implemented the ”seed and extend“ algorithm for read alignment. Point mutations and small indels were detected from reads with imperfect alignments and tandem duplications were detected from reads spanning the duplication junction. Translocations were detected from reads whose ends belonged to preselected fusion partner genes. Results: To benchmark our software we used RNA-seq data from 151 whole-exome/genome-sequenced AML samples studied by The Cancer Genome Atlas Research Network. We show that our software reliably calls clinically important mutations affecting the genes NPM1 (4-nt insertion), FLT3 (substitutions and internal tandem duplications, ITD), MLL partial tandem duplications (PTD), as well as substitutions in CEBPA, IDH1/2, TP53 and RUNX1. Furthermore, we identified gene fusions including PML-RARA, MYH11-CBFB, RUNX1-RUNX1T1, BCR-ABL1 and NUP98-NSD1. Our software is fast and memory efficient and is able to identify the above mutations in less than 20 minutes starting with RNA-seq FastQ files of 100 million 50 bp paired-end reads, using a standard modern laptop computer. In addition, the software operates through a graphical user interface making it accessible to users without programming knowledge. Summary/Conclusion: We demonstrated that clinically important somatic mutations that drives AML can be reliably detected from RNA-seq data alone using our software. As our approach can be readily combined with conventional gene expression analyses of the same RNA-seq dataset, it can be used to generate data with enhanced clinical utility that can improve prognostication and guide patient treatment. As RNA sequencing is a straightforward procedure, our approach can readily enter clinical laboratories, where it can significantly reduce experimental costs and accelerate diagnostic work-ups.

High-Throughput Sequencing Technology for Detection of Gene Mutations in Myeloid Malignancies and Its Clinical Prognostic Significance

Next Generation Sequencing Technology and Its Application in Detecting Gene Mutations

Rapid Detection of Potential New Pathogens in Patient Using High -Throughput Sequencing

Multidimensional Study on the Prognostic Factors of Acute Myeloid Leukemia Patients with FLT3-ITDmutations Based on the Next-Generation Sequencing Platform

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing

Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring

Application of high-throughput gene sequencing in lymphoma

[Application of Next Generation Sequencing for AML/MDS Diagnosis and Treatment].

Identification Of Sequence Variants In Genetic Disease-Causing Genes Using Targeted Next-Generation Sequencing

New-generation high-throughput technologies based 'omics' research strategy in human disease]

The Application of NextGen Sequencing in the Diagnosis of Myeloid Neoplasms in Myeloma Patients With Cytopenia

Research of gene mutation in acute myeloid leukemia: development and prospect

Next-generation sequencing reveals gene mutations landscape and clonal evolution in patients with acute myeloid leukemia

Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next‐generation sequencing technique

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

The impact of next-generation sequencing for diagnosis and disease understanding of myeloid malignancies

Advances in Nanopore and Photoelectron-Based High-Throughput Sequencing Technology for Single-Molecule Sequencing

Next-generation sequencing and its applications in molecular diagnostics

Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms

PS1040 DETECTION OF MRD MAY PREDICT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS

[Mutational Spectrum and Prognosis Analysis of AML Patients Based on High-Throughput Sequencing]